

गोपनीय: Confidential

मिसिलस.- 8(19)/2014डी.पी./एनपीपीए- डीवी-11

F. No. 8(19)/2014/DP/NPPA-Div. II

कार्यवाहीस. : 151/19/2014/F

Proceeding No : 151/19/2014/F

Minutes of the 151<sup>st</sup> and 19<sup>th</sup> meeting of Authority under DPCO, 2013 held on 10<sup>th</sup> December, 2014 at 12.00 Noon

The 151<sup>st</sup> overall meeting of the Authority, which is the 19<sup>th</sup> under the DPCO, 2013 was held on 10<sup>th</sup> December, 2014 at 12.00 Noon under the Chairmanship of Shri Injeti Srinivas, Chairman, NPPA. The following members of the NPPA were present:-

- (i) Shri Amit Khare, Member Secretary, NPPA.
- (ii) Dr. G. N. Singh, Member (Ex-Officio), Drug Controller General (I), Department of Health & Family Welfare.
- (iii) Dr. K.L. Prasad, Member (Ex-Officio), Adviser, Economic Division, Deptt. of Economic Affairs.
- (iv) Shri L.M. Kaushal, Member (Ex-Officio), Director (Cost), Deptt. of Expenditure, Ministry of Finance.

The following officers also attended the meeting and assisted the Authority in its deliberations:-

- (a) From Department of Health & Family Welfare.
  - (i) Shri R. Chandrashekar, Deputy Drug Controller
  - (ii) Smt. Rubina Bose, Asstt. Drug Controller.
- (b) From NPPA
  - (i) Shri A.K. Gautam, Adviser (Cost)
  - (ii) Shri LalSangtur, Director (Overcharging, II)
  - (iii) Shri Jagdish Kumar, Director (M&F)
  - (iv) Shri A.K. Khurana, Director (Pricing & Admn)
  - (v) Shri Naresh Arya, Dy. Director (Cost)
  - (vi) Shri Suneel Chopra, Dy. Director (Legal)

11-12-2014

Chairman, NPPA welcomed all the members present in the meeting.

**1. Agenda Item no. 1: Confirmation of Minutes of the 18<sup>th</sup> Meeting held on 15.9.2014**

1.0 Members of the Authority who participated in the 15<sup>th</sup> and the 18<sup>th</sup> Meeting under DPCO, 2013 confirmed the minutes of the meeting.

**2. Agenda Item no. 2: Action Taken Report**

2.0 Noted.

2.1 The Authority desired that the representations/reviews filed, if any, against the notifications issued/approved during the previous authority meeting, may also be informed in future.

**3. Agenda Item no. 3: Items of price fixation for Scheduled formulations under DPCO, 2013**

3.1 The Authority considered, discussed and approved the prices of three formulation packs for fixing/notifying the ceiling price under Para 4 of DPCO, 2013 based on data furnished by IMS-Health/Pharma Trac/companies. Price fixation of N/2 saline or sodium chloride injection 0.45%w/v was deferred since its proposed ceiling price was higher than the same of Normal Saline (0.9%). The Authority discussed the issue regarding higher ceiling price for lower strength formulation and decided that a proposal for such cases may be sent to DOP recommending that price for such lower strength formulations may be fixed on proportionate basis as per approval of DOP or under para 19 of DPCO 2013.

3.2 The Authority considered, discussed and approved the prices of six formulation packs for fixing/notifying the ceiling price under Para 6 of DPCO, 2013 based on the Monopoly conditions i.e. where data in respect of only one company is available.

3.3 The Table showing the prices approved in respect of each such medicine is given below:

*[Handwritten Signature]*  
10.12.2014

S.No.	Particulars	Approved Revised Price (Price in Rs. including WPI but excl. local taxes)
<b>A</b>		
1	Bleaching Powder	17.42/kg
2	Ketamine Hydrochloride Injection 10mg/ml	10.54/ml
4	Zinc Sulfate Syrup 20mg/5ml	0.61/ml
<b>B</b>		
1	Codeine Phosphate Syrup 15mg/5ml	0.63/ml
2	Diazepam Suppository 5 mg	5.48/suppository
3	Efavirenz capsule 600 mg	59.50/capsule
4	Hormone Releasing IUD	455.01/one IUD
5	Iodine Solution 8mg/5ml	0.32/ml
6	Isosorbide Dinitrate Tablet 20 mg	2.00/tablet

3.4 The Authority discussed and rejected the price of one formulation pack based on the representation from the manufacturing/marketing company since the conditions prescribed under the guidelines approved in the 150<sup>th</sup>/18<sup>th</sup> Authority meeting held on 15.09.2014 for consideration of representation were not complied with.

3.5 The Chairman briefed the Authority regarding various steps taken by NPPA to fix prices of pending formulations which includes writing to State Governments, State Drug Controllers, pharma associations, public notice etc. and said that NPPA had tried all possible ways. It was decided that a note with respect to remaining formulations whose price data is not available, be sent to DOP informing the status and to seek further advice in this regard.

**4. Agenda Item no. 4: Items of price fixation of the Scheduled formulations listed in NLEM, 2011 and included in the DPCO, 2013 as well as DPCO, 1995**

4.1 The Authority discussed and considered the prices of 11 formulation packs which are common in DPCO 2013 as well as in DPCO 1995. The Authority discussed the provisions of Para 10(1) and 10(2) and 16 of DPCO 2013 regarding the fixation/revision of prices of scheduled medicines. It was informed that the Para 10 deals with the pricing of the formulations covered under DPCO 1995 as well as included in the DPCO 2013. The Para 16 deals with the revision of the ceiling prices of scheduled formulations under DPCO 2013 irrespective of their inclusion in DPCO 1995.

10/12/14



The Authority discussed the specific ceiling price (i.e. NCP) and ceiling price fixed under DPCO 1995 and it was noted that these ceiling limits were adhered to while fixing prices under DPCO 2013, for cases under consideration. Further, it was desired that in future, the ceiling prices notified under DPCO, 1995 and overcharging cases, if any, may also be indicated in the agenda.

4.3 The Authority considered, discussed and approved the prices of the following 11 formulation packs for fixing/notifying the ceiling price under Para 4 and 6 of DPCO, 2013.

4.4 A Table showing the prices approved in respect of each such medicine is given below:

Sl. No.	Medicines	Revised CP (incl. WPI but excl. local taxes) (Rs./unit)
<b>A</b>	<b>Cases based on data of the IMS Health/Pharma Trac/Companies</b>	
1	Ascorbic Acid 500mg Tablet	0.94/tablet
2	Cloxacillin capsule 250mg	1.29/capsule
3	Gentamycin Injection 10mg/ml	3.18/ml
4	Glucose Injection 5%	0.06446/ml
5	Glucose Injection 5%+ Normal Saline 0.9%	0.06167/ml
6	Griseofulvin 125mg Tablet	0.75/Tablet
7	Normal Saline 0.9% Injection	0.08596/ml
<b>B</b>	<b>Cases based on Monopoly situations</b>	
1	Ascorbic Acid 100mg Tablet	0.14/tablet
2	Chlorpromazine Injection 25mg/ml	1.22/ml
3	Methyldopa Tablet 250mg	1.69/tablet
4	Vitamin A capsule 50000 IU	0.51/capsule

5. Agenda Item no. 5: Price revision on the review application filed by M/s Ranbaxy in respect of Ciprofloxacin Hydrochloride drop 0.30%.

5.0 - The Authority discussed the proposal of price revision in respect of Ciprofloxacin Hydrochloride drop 0.30%, based on the review order dated 16.09.2014 received from the DOP and approved the revised ceiling price at Rs. 1.49 per ml (including WPI) against the earlier ceiling price of Rs. 1.30 per ml (Rs. 1.38 per ml including WPI)

6. Agenda Item no. 6: Price revision on the review application of M/s Albert David Limited

The Authority discussed the proposal of price revision in respect of Glucose Injection 10% based on the review order dated 16.09.2014 received from the DOP and approved the revised ceiling price at Rs. 0.05316 per ml (including WPI) against the earlier ceiling price of Rs. 0.05 per ml (including WPI).

**7. Agenda Item no. 7: Price revision on the review application of M/s J.B.Chemicals & Pharmaceuticals Limited in respect of Meglumine Diatrizoate Injection 60%.**

7.0 The Authority discussed the proposal of price revision in respect of Sodium Meglumine Diatrizoate Injection 60%, based on the review orders dated 05.11.2014 received from the DOP and approved the revised ceiling price at Rs. 8.05 per ml (including WPI) against the earlier ceiling price of Rs. 4.92 per ml.

**8. Agenda Item no. 8: Price revision on the review application of M/s J.B.Chemicals & Pharmaceuticals Limited in respect of Meglumine Diatrizoate Injection 76%.**

8.0 The Authority discussed the proposal of price revision in respect of Sodium Meglumine Diatrizoate Injection 76%, based on the review orders dated 05.11.2014 received from the DOP and approved the revised ceiling price at Rs. 9.81 per ml (including WPI) against the earlier ceiling price of Rs. 5.84 per ml.

**9. Agenda Item no. 9: Price revision on the review application filed by M/s Abbott in respect of Co-Trimoxazole tablet 160mg + 800mg.**

9.0 The Authority discussed the proposal of price revision in respect of Co-Trimoxazole tablet 160mg + 80mg, based on the review order dated 07.07.2014 received from the DOP and approved the revised ceiling price at Rs. 1.32 per tablet (including WPI) against the earlier ceiling price of Rs. 1.36 per tablet.

**10. Agenda Item no. 10: Price revision on the review application filed by M/s Claris Life Sciences in respect of Mannitol Injection 20%.**

10.0 The Authority discussed the proposal of price revision in respect of Mannitol Injection 20%, based on the review order dated 23.12.2013 received from the DOP and approved the revised ceiling price at Rs. 0.55 per ml (including WPI) against the earlier ceiling price of Rs. 0.37 per ml.

Agenda Item no. 11: Hon'ble Delhi High Court's order/DOP's Review order in re price fixation order S. O. 559(E) dated 14.03.2011 for Dettol Antiseptic Liquid formulation in respect of M/s Reckitt Benckiser (India) Ltd. under para 22 of DPCO 1995.

11.0 Noted.

12. Agenda Item no.12 and additional agenda item regarding fixation of retail price in respect of new drug.

12.0 The Authority discussed the cases of retail price fixation of 54 new drugs (except at S.no. 23 M/s Eli-Lily who has withdrawn the application) based on Form-I applications received from the various company(ies). It was decided that the manufacturing permission granted by the State Licensing Authority before 01.10.2012 and/or its renewals thereafter, if applicable, (as per DCG(I) order F. No. 4-01/2013-DC (Misc 13-PSC) dated 15.01.2013) will continue to be in operation, therefore, Form-I applications of new drugs based on such manufacturing permissions will be considered for price fixation under DPCO, 2013. There are total 27 such cases as mentioned below at (a -13 cases) and (b - 14 cases). In remaining 27 cases of permission after 01.10.2012, as mentioned at (c) below, DCG(I) office will examine the new drug applications in Form I (FDCs) in the light of the abovesaid letter and submit their comments whether the drugs under reference are allowed to be marketed in the country. As regards earlier applications for new drugs in respect of which retail price has already been approved and notified, NPPA will forward the necessary documents to DCG(I) for examination at their end whether any drug under reference is prohibited or not. The Authority also decided that the price notifications already made will not be withdrawn till the outcome of examination received from DCG(I) office.

Accordingly, the summary of such cases are as under:-

- (a) DCG(I)'s permission is available in:- 13 cases
- (b) SDC's permission (before 01.10.2012) and/or its renewal, is available in:- 14 cases
- (c) SDC's permission (after 01.10.2012) is available in:- 27 cases

The details of 27 (13+14 i.e. a+b) approved prices are as under:

*Prasad*  
12-11-13



S.No	Company name/Product name	Approved Price (Rs.)
12(i)	M/s Ahlcon Parenterals (I) Ltd (Manufacturer) and M/s Biochem Pharmaceuticals Limited. (Marketing company) Paracetamol 10mg/ml (Paracetamol infusion 1000mg/100ml) Each ml contains: Paracetamol 10mg	2.10/ml
12(ii)	M/s Ahlcon Parenterals (I) Ltd (Manufacturer) and M/s Cadila Healthcare Limited (Zydus Cadila) (Marketing company) Paracetamol 10mg/ml (Paracetamol Infusion 1000mg/100ml). Each ml contains: Paracetamol 10mg	2.10/ml
12(iii)	M/s Mapra Lab. Ltd (Manufacturer as well as Marketing company) - Amoxicillin Trihydrate eq. to Amoxicillin 875mg. Potassium Clavulanate Diluted eq. to Clavulanic Acid 125mg tablet Each tablet contains: Amoxicillin Trihydrate eq. to Amoxicillin 875mg Potassium Clavulanate Diluted eq. to Clavulanic Acid 125mg	160.00/6's tablet
12(ix)	M/s Acme Formulation Pvt. Ltd (Manufacturer) and M/s Alembic Pharmaceuticals Limited. (Marketing company). Metoprolol succinate eq. to Metoprolol tartarate (in extended release form) - 50mg + Cilnidipine 10mg (Cardiocil M tablet) Each film coated tablet contains: Metoprolol succinate eq. to Metoprolol Tartarate (in extended release form) - 50mg Cilnidipine 10mg	7.66/tablet
12(xiii)	M/s. Theon Pharmaceuticals Ltd. (Manufacturer) and M/s Zuventus Healthcare Ltd (Marketing company) - Cefixime 200mg + Azithromycin 250mg (Trusten AZ tablet) Each film coated tablet contains: Cefixime (as trihydrate) eq. to Anhydrous Cefixime 200mg Azithromycin (as dehydrate) eq. to Azithromycin 250mg	15.88/tablet
12(xiv)	M/s Hetero Labs. Ltd (Manufacturer) and M/s Micro Lab. (Marketing company) - Azithromycin (as dehydrate) eq. to Azithromycin 200mg + Levofloxacin Hemidhydrate eq. to Levofloxacin 250mg (Levobact AZ 250 tablet) Each film coated tablet contains: Azithromycin (as dehydrate) eq. to Azithromycin 250mg Levofloxacin Hemidhydrate eq. to Levofloxacin 250mg	12.15/tablet
12(xv)	M/s Hetero Labs. Ltd (Manufacturer) and M/s Micro Lab. (Marketing company) - Azithromycin (as dehydrate) eq. to Azithromycin 500mg + Levofloxacin Hemidhydrate eq. to Levofloxacin 500mg (Levobact AZ 500 tablet) Each film coated tablet contains:	21.55/tablet

*[Handwritten signature]*  
12/12/2014

	Azithromycin (as dehydrate) eq. to Azithromycin 500mg Levofloxacin Hemidhydrate eq. to Levofloxacin 500mg	
12(xvi)	M/s Adore Pharmaceuticals Pvt. Ltd. (Manufacturer) and M/s Ajanta Pharma Ltd., (Marketing company) - Gatifloxacin 3mg + Prednisolone Acetate 10mg + Benzalkonium Chloride Drops 0.01% (Eye drops). Each ml contains: Gatifloxacin eq. to Gatifloxacin (anhydrous) - 3mg Prednisolone Acetate - 10mg Benzalkonium Chloride 0.01% w/v (as preservative)	2.47/ml
12(xvii)	M/s Orbit Lifescience Pvt. Ltd., (Manufacturer) and M/s Genx Pharma Ltd (Marketing company) - Atorvastatin Calcium 10mg + Clopidogrel 75 mg Capsule (Clopid AT10 capsule) Each hard gelatin capsule contains: Atorvastatin calcium eq. to Atorvastatin 10mg (As pellets) Clopidogrel bisulphate eq. to Clopidogrel 75mg (As pellets)	87.52/10's capsule
12(xix)	M/s Anphar Organics (Manufacturer) and M/s USV Ltd., (Marketing company) - Gliclazide 60mg + Metformin 500mg (Glikey MF 60 sustained release tablet) Each uncoated bilayered sustained release tablet contains: Gliclazide 60mg Metformin 500mg	6.61/tablet
12(xxi)	M/s Theon Pharmaceuticals Ltd (Manufacturer) and M/s Cadila Limited. (Marketing company) - Cefpodoxime Proxetil 200mg & Azithromycin 250mg Tablets Each film coated tablet contains: Cefpodoxime Proxetil eq. to Cefpodoxime IP 200 mg Azithromycin Dihydrate Eq. to Azithromycin Anhydrous IP 250 mg	17.70/tablet
12(xxvi)	M/s. Anphar Organics (Manufacturer) and M/s USV Ltd (Marketing company) - Gliclazide 80mg + Metformin SR 500mg (Glikey MF 80 tablet) Each uncoated bilayered tablet contains: Gliclazide 80mg Metformin 500mg (in sustained release form)	4.63/tablet
12(xxvii)	M/s. Innova Captab (Manufacturer) and M/s Zuventus Healthcare Ltd. (Marketing company) - Povidone Iodine 5% w/w and Ornidazole 1% w/w (Zuventidine OZ ointment) Each gm contains: Povidone Iodine 5% w/w (Available Iodine 0.5% w/w) Ornidazole 1% w/w	3.00/gm
12(xxxi)	M/s Orbit Lifescience Pvt. Ltd. (Manufacturer) and M/s Gnex Pharma Ltd. (Marketing company) - Atorvastatin calcium	110.48/10's



	20mg and Clopidogrel bisulphate 125mg (Clopid AT20) Each hard gelatine capsule contains: Atorvastatin Calcium eq. to Atrovastatin 20 mg (as pellets) Clopidogrel bisulphate eq. To Clopidogrel 125 mg (as pellets) -	capsule
12(xxxiii)	M/s Windlas Biotech Ltd. (Manufacturer) and M/s Cadila Pharmaceuticals Ltd. (Marketing company) - Telmisartan 40mg, Amlodipine 5mg tablet and Hydrochlorothiazide 12.5mg Each uncoated bilayered tablet contains: Telmisartan IP 40 mg Amlodipine besylate IP eq. to Amlodipine 5 mg Hydrochlorothiazide IP 12.5 mg	7.80/tablet
12(xxxiv)	M/s Cadila Pharma (Manufacturer as well as marketing company) - Losartan Potassium 50mg and Chlorthalidone 12.5mg tablet. Each film coated tablet contains: Losartan Potassium 50mg Chlorthalidone 12.5mg	4.55/tablet
12(xxxv)	M/s Panacea Biotech Ltd. (Manufacturer) and M/s Torrent Pharmaceuticals Ltd. (Marketing company) - Paclitaxel 100mg (Human Albumin) - (NAB Tortaxel). Each vial contains: Paclitaxel 100mg (Human Albumin)	7954.28/vial
12(xxxvii)	M/s Sterile-Gene Life Sciences Pvt. Ltd. (Manufacturer) and M/s Merck Ltd. (Marketing company) - L-Thyroxine sodium Tablets 25mcg (Uthyrox 25). Each uncoated tablet contains: L-Thyroxine Sodium IP Equivalent to anhydrous L-Thyroxine Sodium 25 mcg	1.14/tablet
12(xxxviii)	M/s Sterile-Gene Life Sciences Pvt. Ltd. (Manufacturer) and M/s Merck Ltd., (Marketing company) - L-Thyroxine sodium Tablets 75mcg (Uthyrox 75) Each uncoated tablet contains: L-Thyroxine Sodium IP Equivalent to anhydrous L-Thyroxine Sodium 75 mcg	1.25/tablet
12(xxxix)	M/s GKM New Pharma (Manufacturer) and M/s Intas Pharma Ltd. (Marketing company) - Rosuvastatin 10mg and Aspirin 150mg capsule Each hard gelatin capsule contains: Rosuvastatin calcium eq. to Rosuvastatin 10mg (as granules) Aspirin 150mg (as enteric coated tablet)	4.55/capsule
12(XI)	M/s Aeon Formulations Pvt. Ltd. (Manufacturer) and M/s Ajanta Pharma Ltd. (Marketing company) - Rosuvastatin 10mg and Aspirin 150mg capsule	4.55/capsule

12(XLvi)	<p>Each hard gelatin capsule contains:  Rosuvastatin calcium eq. to Rosuvastatin 10mg (as granules)  Aspirin 150mg (as enteric coated tablet)</p> <p>M/s Curetech Skincare (Manufacturer) and M/s Lupin Ltd.,  (Marketing company) - Clobetasol Propionate 0.05% w/w,  Neomycin Sulphate eq to Neomycin 0.1% w/w and Miconazole  Nitrate - 2.0% w/w tube. (Clobetavate NM 10gms cream).</p> <p>Each gm contains:  Clobetasol Propionate 0.05% w/w  Neomycin Sulphate eq to Neomycin 0.1% w/w  Miconazole Nitrate - 2.0%w/w</p>	2.06/gm
12(XLvii)	<p>M/s Aeon formulations Pvt. Ltd. (Manufacturer) and M/s Aristo  Pharmaceuticals Pvt. Ltd., (Marketing company) - Ilprazole  10mg + Domperidone 30mg capsule (Chekcid-D SR capsules)</p> <p>Each hard gelatin capsule contains:  Ilprazole 10mg (as enteric coated tablet)  Domperidone 30mg (as film coated sustained release tablet)</p>	4.37/capsule
12(XLix)	<p>M/s Ajanta Pharma Ltd., (Manufacturer &amp; Marketing company)  - Cyclosporine 0.5mg and Benzalkonium chloride 0.01% eye  drop (Cyclosporine eye Drop 0.05%)</p> <p>Each ml contains:  Cyclosporine 0.5mg  Benzalkonium Chloride 0.01% w/v  (as preservative)</p>	266.25/3ml vial -
12(L)	<p>M/s Pharma Force Lab., (Manufacturer) and M/s Mankind  Pharma Ltd. (Marketing company) - Diclofenac Potassium  50mg and Serratiopeptidase 15mg tablet</p> <p>Each film coated tablet contains:  Diclofenac Potassium - 50mg  Serratiopeptidase -15mg  (30,000 units of Serratiopeptidase)  (as enteric coated granules)</p>	2.70/tablet
12(XLiv)	<p>M/s Curetech Skincare (Manufacturer) and M/s Lupin Ltd.  (Marketing company) - Clobetasol propionate 0.05% w/w,  Neomycin sulphate 0.5% w/w, Miconazole Nitrate 2.0% w/w  and Zinc sulphate 2.0% w/w (Clobetavate GM 10gm cream).</p> <p>Each gm contains:  Clobetasol propionate 0.05% w/w  Neomycin sulphate eq. to Neomycin 0.5% w/w  Miconazole Nitrate 2.0% w/w  Zinc Sulphate 2.0% w/w</p>	1.77/gm
12(XLv)	<p>M/s Mankind Pharma Ltd. (Manufacturer as well as Marketing  company)- Calcium carbonate 200mg, Calcitriol 0.25mcg,  Mecobalamin 1500mcg, Folic Acid 1.5mg and Pyridoxine HCl  3mg capsule.</p>	7.68/capsule

Each soft gelatin capsule contains: Calcium carbonate eq. to Elemental Calcium 200mg Calcitriol 0.25mcg Mecobalamin 1500mcg Folic Acid 1.5mg Pyridoxine HCl 3mg	
--	--

13. **Agenda Item no. 13:-Amendment of Price fixation order no S.O. 1642(E) dated 14.06.2013 –reg.**

13.0 Noted

14. **Agenda Item no. 14: Price revision on the review application filed by M/s Nitin Lifesciences Ltd. in respect of Superspas-RF Injection.**

14.0 The agenda regarding the amendment of notification issued by NPPA vide S.O. 945(E) dated 27.03.2014, in pursuance with the directions issued in the review order of M/s Nitin Lifesciences Ltd. in respect of Superspas-RF Injection passed by DOP, was circulated to the Authority members during the meeting and the members noted the same.

15. **Additional Agenda Items:**

15.1 **Draft proposal for Display of Distinguishing Mark and Ceiling Price/Unit in respect of Scheduled Drugs under DPCO, 2013.**

The Authority was informed that NPPA has invited comments of all stakeholders on draft proposal for display of distinguishing mark and ceiling price / unit in respect of Scheduled under DPCO, 2013. The comments have been received from the eight stakeholders, namely, FOPE, FICCI, IDMA, OPPI, KD&PMA, M/s GSK Pvt Ltd, M/s Sun Pharma and Sh Raj Vaidya - Community Pharmacist, Goa.

It was noted that some stakeholders have also valued this initiative of NPPA and have stated that such steps for display of distinguish mark, ceiling price etc., will benefit the patients, while there are certain concerns that need to be addressed.


The Authority appreciated the initiative of NPPA to bring awareness among the consumer in respect of price controlled drugs and other provisions of the DPCO, 2013. The Authority was of the view that the distinguishing features will benefit the smooth supply of essential drugs.



effective implementation of the DPCO prices and in enhancing the rational use of drugs. However, keeping in view labeling provisions under Drugs and Cosmetic Act, the Authority was of the view that the toll free number on the packaging may be incorporated as first level measure to improve the consumer awareness. It was decided that the Authority should carry forward the proposal in consultation with all stakeholders.

15.2 Scheme of consumer awareness and publicity was noted by the Authority. The proposal for building Consumer Awareness and Publicity through Print, Electronic & other media in collaboration with Ministry of Consumer Affairs was discussed and after deliberation, it was decided that Authority should take forward the proposed publicity campaign on two broad issues (i) Generic Medicines and NLEM, and (ii) DPCO, 2013 and the role of NPPA. It was also decided to establish a web based helpline, for redressing consumer grievances relating to shortage of drugs, refusal to sale, overcharging etc.

16. This issues with the approval of Chairman, NPPA.

  
10.12.2014  
(Amit Khare)  
Member Secretary